trial · primary record
Teverelix DP
Endometriosis Pelvic
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 84 |
| Primary completion | 2029-12 |
| Primary endpoint | Percentage of Participants With Serum Estradiol Maintained Within 20-50 pg/mL for at Least 14 Consecutive Days |
| Registry ID | NCT07914062 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:29.092Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07914062
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.